Tag Archives: public policy

PTO Patent Examinations in the wake of Mayo and Myriad

stopped-media-115x76

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

Biotech CEOs Speak Out on JOBS Act Success

Biotech IPOs Infographic

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. The JOBS Act reached a major milestone last week, with the 100th company going public under its provisions. On October 7th at the 13th Annual BIO Investor Forum, we Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Partners for Healthy Dialogues: Letter to CMS

Partners for Health Dialogues

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in a letter to the Center for Medicare and Medicaid Services highlighting both their shared commitment to sunshine and the importance of context in the upcoming data release.  As BIO CEO Jim Greenwood said in a Q&A with P4HD: “We believe that part of CMS’s public service function in this area should be to help improve the public’s understanding of the need for Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Video: Emerging Company CEOs Praise JOBS Act

medical_research

Passed in 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. In this short video, leading BIO Board Members and biotech company CEOs share the reasons why they feel the JOBS Act is critically important for today’s biotech industry. The JOBS Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,